ARI-0001

DB30635InvestigationalCell transplant therapies

ARI-0001 is a biologic drug. ARI-0001 is under investigation in clinical trial NCT05641428 (Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL).

Mechanism: Pharmacologically active on B-lymphocyte antigen CD19
Curator reviewed
Code names: ARI-0001

Resolves to

Targets

P15391CD19

What you can answer from here — as of July 01, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with ARI-0001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account